Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02885649 · ClinicalTrials.gov registry record · Early Phase 1
Enzalutamide Before Surgery in Treating Patients With Kidney Cancer
A Early Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT02885649 is a Early Phase 1 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 3 participants.
The verdict
NCT02885649, a Early Phase 1 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow. Anti-hormone therapy, such as enzalutamide, may lessen the amount of androgens produced by the body and keep kidney tumors from growing.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Enzalutamide
- PROCEDURE Nephrectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-12-05 |
| Est. Completion | 2020-03-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02885649
The ClinicalTrials.gov registry entry for NCT02885649 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02885649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02885649 about?
NCT02885649 is a clinical study titled "Enzalutamide Before Surgery in Treating Patients With Kidney Cancer". This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow. Anti-hormone therapy, such as enzalutamide, may lessen the amount of androgens produced by t...
What is the current status of trial NCT02885649?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2017-12-05. Estimated completion is 2020-03-02.
What interventions are being tested in trial NCT02885649?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Enzalutamide (DRUG), Nephrectomy (PROCEDURE).
Who is sponsoring clinical trial NCT02885649?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.